Training in Congenital and Acquired Heart Disease

 描述（由申请人提供）：这个联合俄亥俄州州立大学（OSU）-全国儿童医院（NCH）机构T32博士后项目的竞争性更新的目标是提供先天性和获得性心脏病的跨学科，翻译和最先进的研究培训。该计划提供了一个独特的机会，专注于从胎儿生命到衰老的先天性和获得性心脏病的连续性，并比较这些不同人群之间的疾病机制和结果。其基本原理是，心脏病治疗和预防方面的进展最有可能源于促进医生科学家和基础科学家之间合作的转化研究计划。我们将扩大正在进行的努力，以提供一个学术环境，培养真正的“双向”研究，使我们的医生科学家确定的重大临床问题可以在实验室中得到解决，在板凳上的关键发现可以迅速转化为更大的动物研究和回到床边。 此更新申请寻求每年6名学员，为期5年，承诺2-3年。研究员将从MD，DVM，Pharm.D.中选择。或对心血管研究有浓厚兴趣并致力于疾病导向研究的博士生。项目主任在转化心血管研究和指导方面有着良好的记录，并将在各自的机构担任主要主任。培训计划设计包括正式的学术课程，研讨会和期刊俱乐部，为学员提供心脏病的概述和深入的心脏研究方向。学员将参加一个量身定制的“生存技能”课程，其中包括与专业发展有关的各种单元和讲习班。每个学员将在导师的实验室进行独立的研究项目。由34个校外资助的基础和临床科学导师和3个参与教师所涵盖的研究领域由他们与NCH心脏中心的个人联系代表 以及俄亥俄州的戴维斯心肺研究所。一个新的临床研究者途径被添加到培训计划，以提高医学博士研究员的临床研究机会。该途径将由J.菲尔扫罗，医学博士，国际公认的医生，科学家和儿科主席。描述了一个积极的代表性不足的少数民族招聘和保留计划，以增加学员的多样性。将采用一个跨机构系统对受训人员和导师进行评价。确定成功的总体指标包括内部和外部咨询委员会的详细审查以及每个学员个人发展计划的成功执行。受训人员的具体指标包括完成所需的课程，由指导团队进行年度评估，以及通过同行评审的手稿和摘要，在国家会议上的演讲和赠款提交（NIH K，R21和/或基金会赠款）的数量评估的研究生产力。

 DESCRIPTION (provided by applicant): The objective of the competitive renewal of this joint Ohio State University (OSU)-Nationwide Children's Hospital (NCH) institutional T32 postdoctoral program is to provide interdisciplinary, translational, and state- of-the-art research training in congenital and acquired heart disease. This plan provides a unique opportunity to focus on a continuum of congenital and acquired heart disease from fetal life to senescence and to compare disease mechanisms and outcomes between these diverse populations. The rationale is that advances in heart disease therapy and prevention are most likely to originate from a translational research program that fosters collaboration between physician-scientists and basic scientists. We will expand ongoing efforts to provide an academic environment to cultivate true `bidirectional' research, so that significant clinical problems identified by our physician scientits can be addressed in the laboratory, and key findings at the bench can be rapidly translated to larger animal studies and back to the bedside. This renewal application seeks 6 trainees per year for 5 years with a 2-3 year commitment. Fellows will be selected from MD, DVM, Pharm.D. or PhD trainees who have strong interests in cardiovascular research and are committed to careers in disease-oriented investigations. The Program Directors have a strong-track record in translational cardiovascular research and mentoring and will serve as the primary directors at their respective institutions. The training plan design consists of formal academic courses, seminars and journal clubs to provide trainees with an overview of heart disease and an in-depth cardiac research orientation. Trainees will participate in a tailor-made "survival skills" course comprised of various modules and workshops related to professional development. Each trainee will perform independent research projects in a mentor's laboratory. The research areas encompassed by the 34 extramurally-funded basic- and clinical- science mentors and 3 participating faculty are represented by their individual affiliations with The Heart Center at NCH and The Davis Heart and Lung Research Institute at Ohio State. A new clinical investigator pathway is added to the training program to enhance clinical research opportunities for MD fellows. The pathway will be directed by J. Phil Saul, MD, an internationally recognized physician-scientist and Chair of Pediatrics. An aggressive underrepresented minority recruitment and retention plan is described to increase trainee diversity. A cross-institutional system will be used to perform trainee and mentor evaluations. Overall metrics to determine success include programatic review by internal and external advisory committees and the successful execution of each trainee's individual development program. Trainee-specific metrics include completion of required coursework, annual evaluation by the mentoring team, and research productivity as assessed by the number of peer-reviewed manuscripts and abstracts, presentations at national meetings and grant submissions (NIH K, R21 and/or foundation grants).